MyoKardia Presents Cardiac Imaging Data from 30-Week EXPLORER-HCM Study of Mavacamten
15. November 2020 16:30 ET
|
MyoKardia, Inc.
EXPLORER-HCM Cardiac Imaging Data Presented at AHA 2020 Scientific Session with Simultaneous Publication in Circulation Mavacamten Treatment Resulted in Favorable Effect on Cardiac Structure --...
MyoKardia Presents Mavacamten Clinical and Non-Clinical Data at the American Heart Association’s Scientific Sessions 2020
13. November 2020 10:00 ET
|
MyoKardia, Inc.
ECHO Data from EXPLORER-HCM Show Mavacamten Treatment Improved Cardiac Structure and Mitral Valve Function in Obstructive Hypertrophic Cardiomyopathy Patients Markers of Physical Activity from...
MyoKardia Collaborates with the American College of Cardiology and PINNACLE/Veradigm to Launch Patient Registry of Hypertrophic Cardiomyopathy
11. November 2020 08:30 ET
|
MyoKardia, Inc.
BRISBANE, Calif. and WASHINGTON, Nov. 11, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ: MYOK), and the American College of Cardiology (ACC) announced the establishment of a nationwide registry...
MyoKardia Reports Third Quarter 2020 Financial Results
05. November 2020 16:13 ET
|
MyoKardia, Inc.
BRISBANE, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today reported financial results for the third quarter ended September 30, 2020. Recent Clinical Program...
MyoKardia Announces Awardees of the Second Annual MyoSeeds™ Research Grants Program
04. November 2020 08:30 ET
|
MyoKardia, Inc.
BRISBANE, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced three awardees of the 2020 MyoSeeds™ Research Grant Program, who have been selected to receive...
MyoKardia Announces Multiple Abstracts Selected for Presentation at the Upcoming American Heart Association’s Annual Scientific Sessions 2020
02. November 2020 08:30 ET
|
MyoKardia, Inc.
BRISBANE, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced the upcoming presentation of clinical and non-clinical data related to mavacamten, MyoKardia’s...
MyoKardia Doses First Patient in Phase 2 Clinical Trial of Danicamtiv in Genetic Dilated Cardiomyopathy
09. September 2020 08:00 ET
|
MyoKardia, Inc.
BRISBANE, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that the first patient has been dosed in the company’s Phase 2 clinical trial of danicamtiv...
MyoKardia to Participate in September Investor Conferences
02. September 2020 08:00 ET
|
MyoKardia, Inc.
BRISBANE, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced its participation in the following upcoming investor conferences: Citi’s 15th Annual BioPharma...
MyoKardia Presents Results from Phase 3 EXPLORER-HCM Clinical Trial of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
29. August 2020 09:30 ET
|
MyoKardia, Inc.
EXPLORER-HCM Data Presented During Live Hot Line Session at ESC Congress 2020 with Simultaneous Publication in The Lancet Presentation Expands on Positive Topline Results Showing Early, Sustained...
MyoKardia and LianBio Form Strategic Partnership to Develop and Commercialize Mavacamten Together in Greater China
11. August 2020 07:35 ET
|
MyoKardia, Inc.
Near-Term Focus on Pursuing Approval of Mavacamten for Obstructive HCM Innovative Model Focused on Long-Term Value Creation: MyoKardia Receives Equity Position in Lian Cardiovascular and Tassos...